TIDMSHP
Directors/PDMR Shareholding
November 3, 2009 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company (the "Company"), announces that on November 2, 2009,
it was notified of the acquisition, on November 2, 2009, of American Depository
Shares ("ADSs") in the Company by Persons Discharging Managerial
Responsibilities as set out below, following the close of a 12 month offering
period under the Shire Employee Stock Purchase Plan. The purchase price of the
ADSs was US$33.54.
Name Number of ADSs
Barbara Deptula 372
Sylvie Gregoire 372
Anita Graham 372
This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)
of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
Investor Cléa Rosenfeld (Rest of the World) +44 1256 894 160
Relations
Eric Rojas (North America) +1 617 551 9715
Notes to editors
SHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit hyperactivity disorder (ADHD), human
genetic therapies (HGT) and gastrointestinal (GI) diseases as well as
opportunities in other therapeutic areas to the extent they arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are focused
on products in specialist markets with strong intellectual property protection
and global rights. Shire believes that a carefully selected and balanced
portfolio of products with strategically aligned and relatively small-scale
sales forces will deliver strong results.
For further information on Shire, please visit the Company's website:
www.shire.com.
2
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Press Release
www.shire.com
END
|